The Technical Analyst
Theratechnologies Inc [THTX]
Exchange: NasdaqCM Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Theratechnologies Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.68% $2.22
Last updated: 7 aug 2022 - 23:40
TimeZone: America/New_York
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 210.69 mill |
| EPS: | -0.367 |
| P/E: | 0.000 |
| Earnings Date: | Oct 11, 2022 |
| SharesOutstanding: | 95.12 mill |
| Avg Daily Volume: | 0.0448 mill |
| RATING 2022-08-05 |
|---|
| B- |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$2.48 (11.96%) $0.265 |
| Date: 2022-08-08 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.11 - 2.32 ( +/- 4.70%) |
| ATR Model: 14 days |
Forecast:
16:00 - $2.22
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.22
Forecast 2: 16:00 - $2.22
Forecast 3: 16:00 - $2.22
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.22 (0.68% ) |
| Volume | 0.0386 mill |
| Avg. Vol. | 0.0448 mill |
| % of Avg. Vol | 86.23 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
THTX
Theratechnologies, Inc. is a pharmaceutical company. The company is headquartered in Montreal, Quebec and currently employs 32 full-time employees. The firm addresses medical needs to promote healthy living for human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy. EGRIFTA is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference of approximately 100 centimeters for males and approximately 90 centimeters for females. Ibalizumab is a cluster difference 4 (CD4)-directed HIV entryinhibitor, which focuses on treating multidrug resistant HIV-1 infection (MDR HIV-1). Ibalizumab binds to the second extracellular domain of the CD4 receptor. Ibalizumab has completed the Phase III trial. EGRIFTA is available in Canada and in the United States. The firm distributes EGRIFTA in the United States through RxC Acquisition.
Latest Press Releases
2022-07-28 11:19:00 - Press Release
Theratechnologies Trogarzo® Data At Aids 2022 Shows Potential For Improved Treatment Regimens
Montreal, july 28, 2022 (globe newswire) -- theratechnologies inc. (“theratechnologies” or the “company”) (tsx: th) (nasdaq: thtx), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced data from two poster presentations at the 24th international aids conference (“aids 2022”), being held from july 29 to august 2 in montreal, canada and virtually. the new data provide key understandings on the potential of trogarzo® (ibalizumab) to evolve treatment paradigms for heavily treatment-experienced hiv populations on complex regimens.
2022-07-27 18:47:00 - Press Release
Theratechnologies Announces Closing Of Funding Of $40 Million Under The Terms Of Its Credit Agreement
This news release constitutes a “designated news release” for the purposes of the company's prospectus supplement dated december 16, 2021 to its short form base shelf prospectus dated december 14, 2021. this news release constitutes a “designated news release” for the purposes of the company's prospectus supplement dated december 16, 2021 to its short form base shelf prospectus dated december 14, 2021.
2022-07-14 07:30:00 - Press Release
Theratechnologies Reports Second Quarter And First Half Fiscal 2022 Financial Results And Provides Business Update
– q2 2022 consolidated sales growth of 8.3% to $19.3 million
2022-07-14 06:30:00 - Press Release
Theratechnologies Provides Update On The Dose Escalation Portion Of Fast Track Designated Th1902 First-in-human Study In Advanced Resistant Malignancies
Montreal, july 14, 2022 (globe newswire) -- theratechnologies inc. (“theratechnologies” or “the company”) (tsx:th) (nasdaq:thtx), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today provided an update on the dose escalation portion of the th1902 phase 1 clinical safety study. this is theratechnologies' first-in-human study of th1902, its investigational lead peptide drug conjugate (“pdc”) linked to docetaxel for the treatment of sortilin-expressing cancers. it has received fast track designation from the united states food and drug administration (“fda”).
2022-07-13 07:40:00 - Press Release
Theratechnologies Announces Binding Commitment For A Non-dilutive Term Loan Of Up To $100 Million From Marathon Asset Management
Financing will significantly strengthen the balance sheet and extend cash runway
Latest News
2022-08-02 07:30:00 - GlobeNewsWire
Theratechnologies to Present at the Canaccord Genuity 42nd Annual Growth Conference
MONTREAL, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 1:00 p.m. ET.
2022-07-14 13:42:04 - Seeking Alpha
Theratechnologies Inc. (THTX) CEO Paul Levesque on Q2 2022 Results - Earnings Call Transcript
Theratechnologies Inc. (NASDAQ:THTX ) Q2 2022 Earnings Conference Call July 14, 2021 8:30 AM ET Company Participants Elif McDonald - Senior Director, Investor Relations Paul Levesque - President & CEO Philippe Dubuc - SVP & CFO Christian Marsolais - SVP & Chief Medical Officer John Mullaly - IR, LifeSci Advisors Conference Call Participants Edward Nash - Canaccord Genuity Andre Uddin - Research Capital Endri Leno - National Bank Operator Good morning and welcome to the Theratechnologies' Second Quarter Fiscal Year 2022 Earnings Call. [Operator Instructions].
2022-07-14 12:15:07 - Benzinga
Theratechnologies Stock Jumps After Q2 Earnings, FY22 Guidance
Theratechnologies Inc (NASDAQ: THTX) issued an update on the dose escalation portion of the TH1902 Phase 1 safety study. 18 heavily pretreated patients were enrolled.
2022-04-25 16:16:00 - GlobeNewsWire
Theratechnologies to Present at Bloom Burton & Co. Healthcare Investor Conference 2022
Presentation time starts on Tuesday, May 3rd at 1:30PM ET Presentation time starts on Tuesday, May 3rd at 1:30PM ET
2022-04-13 14:55:04 - Seeking Alpha
Theratechnologies Inc. (THTX) CEO Paul Levesque on Q1 2022 Results - Earnings Call Transcript
Theratechnologies Inc. (NASDAQ:THTX ) Q1 2022 Earnings Conference Call April 12, 2022 8:30 AM ET Company Participants Paul Levesque - President & CEO Philippe Dubuc - SVP & CFO Christian Marsolais - SVP & Chief Medical Officer John Mullaly - IR, LifeSci Advisors Conference Call Participants Andre Uddin - Mackie Research Capital Stephen Kwai - National Bank Financial Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to Theratechnologies First Quarter Fiscal Year 2022 Earnings Conference Call.
2022-03-31 17:05:00 - GlobeNewsWire
Theratechnologies to Announce Financial Results for Its First Quarter 2022
MONTREAL, March 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its first quarter of fiscal 2022 ended February 28, 2022 on Wednesday, April 13, 2022.
2022-03-08 16:31:00 - GlobeNewsWire
Theratechnologies to Present Three Posters at AACR Including New In Vivo TH1902 Preclinical Data Demonstrating Tumor Growth Inhibition of Human Cancer Stem-Like Cells (CD133+) in Both Triple-Negative Breast and Ovarian Cancers
MONTREAL, March 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that three poster abstracts have been accepted for presentation at the 2022 Annual Meeting of the American Association for Cancer Research (AACR) to be held April 8-13, 2022 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The Company will present new in vivo TH1902 preclinical data demonstrating tumor growth inhibition of human cancer stem-like cells (CD133+) in both triple-negative breast and ovarian cancers. Theratechnologies will also present new in vivo data on anti-cancer efficacy of TH1902 against ovarian and endometrial cancers, in addition to the inhibitory effect of TH1902 on subcutaneous melanoma xenografts and formation of lung metastases in a syngeneic mouse model.
2022-02-27 10:14:27 - Seeking Alpha
Theratechnologies Inc. (THTX) CEO Denis Boucher on FY2021 Results - Earnings Call Transcript
Theratechnologies Inc. (THTX) CEO Denis Boucher on FY2021 Results - Earnings Call Transcript
2022-02-10 07:00:00 - GlobeNewsWire
Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021
MONTREAL, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its fourth quarter of fiscal 2021 ended November 30, 2021 as well as for its full fiscal year 2021 on Thursday, February 24, 2022.
2021-11-03 07:30:00 - GlobeNewsWire
Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021
MONTREAL, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer, will present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021 at 9:40 a.m. ET.